NEW YORK (GenomeWeb) – Exact Sciences reported after the close of the market on Tuesday that its second quarter revenues rose 172 percent year over year, driven by a 149 percent increase in the number of completed Cologuard colon cancer tests.

For the three months ended June 30, the molecular diagnostics company reported revenues of $57.6 million, up from $21.2 million a year earlier, and significantly beating analysts' consensus estimate of $49.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.